Regeneron Fires Back at DOJ’s Charges of False Claim Act Violations

The Department of Justice’s complaint against Regeneron that the company’s single cash-or-credit price is a violation of the False Claims Act “is not only incompatible with the text of the relevant statute and regulations, but divorced from reality,” the company says in a recent filing.
Source: Drug Industry Daily